The Biotech Crossroads: Inside Sarepta's Shakeup and Vor's PivotGlobal Report·22 hours agoSRPT+9.49%VOR+1.29%
US Rare Disease Biotechs Navigate Regulatory Scrutiny and Revised 2026 GuidanceGlobal Report·Aug 13 at 04:42 AMSRPT+9.49%
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)Tip Ranks·Aug 6 at 06:19 AMSRPT+9.49%SRPU0.00%
Sarepta Q2 FY26 net income turns to USD 4.89 million loss; revenue drops 34% to USD 401.25 millionPUBT·Aug 5 at 03:09 PMSRPT+9.49%SRPU0.00%
The Overlooked Summer Shakeups: Spinoffs, FDA Drama, and Insider BetsGlobal Report·Aug 4 at 04:17 AMTRIP+1.66%SRPT+9.49%
Stop Buying the AI Buzzwords and Look at Who is Actually Printing MoneyGlobal Report·Jul 31 at 04:21 AMEQIX-0.26%AZO+0.12%
Sarepta Therapeutics (SRPT) Could Be 28% Below Fair Value As New CEO Takes OverSimplywall·Jul 30 at 10:23 AMSRPT+9.49%SRPU0.00%
Tracking Specialized Equities: Fox's Roku Buyout and Key C-Suite Reshuffles Drive Idiosyncratic FlowGlobal Report·Jul 30 at 04:13 AMZTS+3.68%SRPT+9.49%
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from BrokeragesMarket Beat·Jul 30 at 01:14 AMSRPT+9.49%SRPU0.00%
